Ruth
Duncan offers her perspective of the challenges and opportunities for the polymer
therapeutics community. She discusses
recent clinical successes and failures and offers valuable suggestions which
could improve translation of products from the lab to the clinic. Key considerations include (amongst others) appropriate
selection of polymer and drug for a specific application, sufficient materials
characterization (not just biological analysis), clinically relevant
preclinical models and improved clinical trial design.
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?, R.Duncan,
Journal of Controlled Release, http://dx.doi.org/10.1016/j.jconrel.2014.05.001
http://www.sciencedirect.com/science/article/pii/S0168365914002922
No comments:
Post a Comment